摘要
目的 :观察卡介苗 (BCG)联合白细胞介素 2 (IL 2 )膀胱灌注防治浅表性膀胱癌术后复发的疗效。方法 :将46例浅表性膀胱癌术后患者随机分为治疗组和对照组各 2 3例 ,治疗组术后 1周给予BCG 60mg加IL 2 5× 10 5U溶于 5 0mL 0 .9%氯化钠注射液中 ,经导尿管注入膀胱 ,保留 2h。期间患者每 2 0min变换体位。每周灌注 1次 ,连续 6次后 ,改为每月 1次 ,共持续 2a。对照组用丝裂霉素C(MMC) ,用量每次 2 0mg ,灌注方法同治疗组。结果 :两组各有 1例失访 ,其余44例随访 13～ 3 2个月 ,平均 2 3 .6个月。 7例复发 ,其中治疗组 2例 ,复发率 9.1% ,对照组 5例 ,复发率 2 2 .7%。结论 :BCG联合IL
Objective:To survey the effect of BCG combined with IL 2 in the prevention of tumor recurrence after the operation for superficial bladder cancer. Methods:After the operation for superficial bladder cancer, 46 patients were randomly divided into the treatment group and control group, with 23 cases each. One week after the surgery, patients of the treatment group began to be subjected each to a weekly intravesical instillation of 60 mg BCG and 5×10 5 U of IL 2 in 50 mL of 0.9% sodium chloride injection through a catheter. The solution was retained in the bladder for 2 hours. During this time, the patients were asked to change their posture every 20 min. 6 weeks later, the instillation was changed from weekly to monthly. The total course lasted 2 years. Patients of the control group received each 20 mg of mitomycin C (MMC) for each intravesical instillation in the same manner as described. Results:In a follow up study of 44 patients lasting 13 32 months (with an average of 23.6 months), 7 patients were found to suffer tumor recurrence. Of these, 2 were from the treatment group, the rate of recurrence being 9.1%, while 5 were from the control group, the rate of recurrence being 22.7%. The remaining 2 patients were missed in the follow up study, one from each group. Conclusion:The effect of intravesical instillation of BCG combined with IL 2 is obviously better than that of MMC in the prevention of tumor recurrence in patients after operation of superficial bladder cancer.
出处
《医药导报》
CAS
2002年第9期547-548,共2页
Herald of Medicine
